Tarsus Pharmaceuticals posts record $194.6m XDEMVY quarter
Tarsus Pharmaceuticals has reported third-quarter 2026 net product sales of $194.6 million for its lotilaner eye drop XDEMVY, a 64% increase on the $118.7 million recorded in the same period of 2025. The result also pushed cumulative net product sales past the $1 billion mark since the product's launch, alongside the milestone of more than one million bottles dispensed.
The Irvine, California-based company said the number of eye care professionals prescribing XDEMVY at least daily rose approximately 20% between the start and end of the quarter, even as it characterised the period as seasonally softer for prescription eye care. Refills accounted for roughly 20% of prescriptions, a figure Tarsus said reflects retreatment becoming an established part of clinical practice. Direct-to-consumer advertising drove a 75% increase in what the company terms high-value actions, with prescription conversion rates above last year's comparable period.
Gross margins held at approximately 93%, consistent with the prior year. The headline net loss of $668.3 million compares with a loss of $12.6 million in Q3 2025, though the disparity is almost entirely explained by $632.2 million in acquired in-process research and development charges arising from the Q3 acquisitions of iRenix Medical and Alkeus Pharmaceuticals. Excluding those one-time charges, underlying operating losses were more modest, driven by expanded R&D and commercial spending to support pipeline programmes and XDEMVY promotional activity. Cash, cash equivalents and marketable securities stood at $309.6 million at 30 September 2026.
Pipeline milestones ahead
Tarsus has four active clinical programmes beyond XDEMVY. TP-04, a gel formulation of lotilaner being studied for ocular rosacea, is in a Phase 2 trial called Kore, with topline data expected in the first half of 2027. TP-05, an oral formulation of lotilaner aimed at preventing Lyme disease by killing ticks before transmission, completed enrolment in its Phase 2 Calliope trial; results are also due in the first half of 2027 and are intended to form the basis of a Phase 3 package.
The two acquired assets add further near-term read-outs. IRX-101, a chlorine dioxide-based ocular antiseptic acquired with iRenix Medical, is expected to enter a Phase 3 study called Comfort in the first half of 2027, targeting reduction of post-procedural pain and corneal toxicity in patients receiving intravitreal injections. Gildeuretinol, a small-molecule oral treatment for Stargardt disease acquired via Alkeus, is currently in the global Phase 3 Northstar trial, with topline data anticipated in 2029. Stargardt disease is a rare inherited retinal disorder for which no FDA-approved therapy currently exists, giving the programme potential orphan-drug advantages.
Tarsus also appointed Neera Clase as Chief Commercial Officer during the quarter.
Market context
XDEMVY holds a notable regulatory position as the only FDA-approved therapy specifically indicated for Demodex blepharitis, a condition caused by mite infestation of the eyelid margin. The absence of approved alternatives has allowed Tarsus to build the category from scratch, with market-creation spending forming a large share of its SG&A line. Data presented at the American Academy of Optometry during the quarter found Demodex blepharitis in 65% of patients presenting with chalazia or hordeola, rising to 91% in recurrent cases, suggesting meaningful under-diagnosis that the company is actively addressing through physician education. At 73% patient-reported symptom improvement at nine months versus 29% for non-lotilaner options in an observational study, the real-world evidence profile Tarsus is building will be important for maintaining formulary positioning and justifying continued DTC investment as the product matures.